omaveloxolone capsules, 40 mg

DRUG2 trials

Sponsors

Biogen

Conditions

Friedreich AtaxiaMItochondrial Myopathies

Phase 2

RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

CompletedNCT02255422

BiogenMItochondrial Myopathies

Start: 2015-05-05End: 2017-11-30Updated: 2025-06-05

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

CompletedNCT02255435

BiogenFriedreich Ataxia

Start: 2015-01-31End: 2025-12-19Updated: 2026-09-03

Related Papers

P.064 MOXIe clinical trial overview of omaveloxolone for patients with Friedreich ataxia

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques2025-06-01

Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants

The Journal of Clinical Pharmacology2025-02-074 citations

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling

CPT Pharmacometrics & Systems Pharmacology2024-09-026 citations

Evaluating the therapeutic efficacy of SKYCLARYS: a promising FDA-approved drug for Friedreich ataxia treatment

International Journal of Surgery Global Health2024-01-01

Efficacy of Omaveloxolone in Friedreich’s Ataxia: Post-Hoc Analysis Using Global Statistics Test to Strengthen Secondary Endpoint Analyses (P8-11.011)

Neurology2023-04-25

Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (<scp>MOXIe</scp> Study)

Annals of Neurology2020-10-17272 citations

P0222KIDNEY EFFECTS IN THE MOXIE TRIAL: A STUDY OF OMAVELOXOLONE IN PATIENTS WITH FRIEDRICH'S ATAXIA

Nephrology Dialysis Transplantation2020-06-014 citations

Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial.

2020-01-0243 citations

Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia.

2018-11-10128 citations

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

2017-08-2938 citations